NCT06324045 Deprescribing Intervention for Patients With Chronic Kidney Disease
| NCT ID | NCT06324045 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hamad Medical Corporation |
| Condition | Chronic Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 424 participants |
| Start Date | 2024-02-19 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 424 participants in total. It began in 2024-02-19 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented. In general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes.
Eligibility Criteria
Inclusion Criteria: Patients who are: * diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic. * receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months. * able to communicate in Arabic and/or English. Exclusion Criteria: * Unstable or has a psychiatric condition. * Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger). * Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients. * Patients with limited life expectancy (less than 6 months).
Contact & Investigator
Hasan Al-Malki, MD
STUDY CHAIR
Head of Nephrology Division, Hamad Medical Corporation
Frequently Asked Questions
Who can join the NCT06324045 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06324045 currently recruiting?
Yes, NCT06324045 is actively recruiting participants. Contact the research team at Ahamad9@hamad.qa for enrollment information.
Where is the NCT06324045 trial being conducted?
This trial is being conducted at Doha, Qatar.
Who is sponsoring the NCT06324045 clinical trial?
NCT06324045 is sponsored by Hamad Medical Corporation. The principal investigator is Hasan Al-Malki, MD at Head of Nephrology Division, Hamad Medical Corporation. The trial plans to enroll 424 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.